{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05069831",
            "orgStudyIdInfo": {
                "id": "GCO 21-0781"
            },
            "organization": {
                "fullName": "Icahn School of Medicine at Mount Sinai",
                "class": "OTHER"
            },
            "briefTitle": "JAK Inhibition in Food Allergy",
            "officialTitle": "JAK Inhibition in Food Allergy",
            "therapeuticArea": [
                "Other"
            ],
            "study": "jak-inhibition-in-food-allergy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-05-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-25",
            "studyFirstSubmitQcDate": "2021-09-25",
            "studyFirstPostDateStruct": {
                "date": "2021-10-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Scott Sicherer",
                "investigatorTitle": "Professor, Pediatrics",
                "investigatorAffiliation": "Icahn School of Medicine at Mount Sinai"
            },
            "leadSponsor": {
                "name": "Icahn School of Medicine at Mount Sinai",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study will assess the role for an oral targeted medication, abrocitinib, as a new treatment option for food allergy patients that would avoid injections. Abrocitinib, which has successfully completed phase three trials for atopic dermatitis, could serve as a single therapy for two conditions in many patients with multiple atopic conditions."
        },
        "conditionsModule": {
            "conditions": [
                "Food Allergy"
            ],
            "keywords": [
                "Food Allergy",
                "JAK",
                "JAK Inhibitor",
                "Abrocitinib",
                "Immunoglobulin E"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "This is a single center, blinded, randomized pilot study.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Abrocitinib 100mg",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "This arm will receive 100mg of the study drug",
                    "interventionNames": [
                        "Drug: Abrocitinib"
                    ]
                },
                {
                    "label": "Abrocitinib 200mg",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "This arm will receive 200mg of the study drug",
                    "interventionNames": [
                        "Drug: Abrocitinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Abrocitinib",
                    "description": "Abrocitinib daily for 4 months",
                    "armGroupLabels": [
                        "Abrocitinib 100mg",
                        "Abrocitinib 200mg"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "change in basophil activation",
                    "description": "change in basophil activation as measured by %CD63 AUC",
                    "timeFrame": "baseline and after 4 months of treatment"
                },
                {
                    "measure": "change in skin prick test",
                    "description": "change in skin prick test size after four months of therapy.",
                    "timeFrame": "baseline and after 4 months of treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "change in antigen-specific T-cell",
                    "description": "change in antigen-specific T-cell response",
                    "timeFrame": "baseline and after 4 months of treatment"
                },
                {
                    "measure": "change in specific immunoglobulin E (sIgE)",
                    "description": "change in sIgE to allergic trigger food(s)",
                    "timeFrame": "baseline and after 4 months of treatment"
                },
                {
                    "measure": "change in FENO",
                    "description": "Fractional Exhaled Nitric Oxide (FeNO) level",
                    "timeFrame": "baseline and after 4 months of treatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 - 50 years old\n* Participant must be able to understand and perform informed consent.\n* IgE-mediated food allergy to at least one of the following foods as defined by (regarding at least one of the foods):\n\n  \u00b0 Foods: peanut, cashew, walnut, hazelnut, sesame, cod, and/or shrimp, history of an acute allergic reaction (urticaria, angioedema, cough, wheeze, and/or repetitive vomiting within an hour of ingestion, and history of positive skin or serum IgE test, and current strict avoidance of the food, and current possession of physician-prescribed self-injectable epinephrine, and skin test wheal 5 mm or greater average diameter\n* Current or past eczema.\n* If female of childbearing potential, must have a negative pregnancy test (serum or urine) and agree to abstinence or acceptable contraception.\n* Plan to remain in the Tri-State area during the trial for visits.\n* Must agree to avoid prolonged exposure to the sun and not to use tanning booths, sunlamps, or other ultraviolet (UV) light sources during the study.\n* If receiving concomitant medications for any reason other than AD, must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1 and through the duration of the study.\n\nExclusion Criteria:\n\n* Unwilling or unable to give written informed consent or comply with protocol.\n* Unable to swallow pill.\n* Use of dupilumab within 6 weeks of enrollment.\n* Prior use or allergy to drugs related to abrocitinib (ruxolitinib, upadacitinib, etc).\n* Use of any other biologic (monoclonal antibody) medication within 12 weeks or 5 half-lives of drug, if known.\n* Allergy to any excipients within abrocitinib.\n* Use of build-up environmental immunotherapy; any food oral immunotherapy;or systemic oral, IV or IM steroids including but not limited to- prednisone, methylprednisolone, prednisolone, solumedrol, solucortef, dexamethasone in the past 4 weeks or 5 half-lives of drug, if known.\n* Use of CYP2C9 and CYP2C19 inducers (such as carbamazepine, norfluoxetine, etc.) within 5 half-lives of the inducer plus 14 days prior to the first dose of study intervention.\n* Use of CYP2C9 and CYP2C19 inhibitors within 1 week of first dose of study intervention or within 5 half-lives (if known) of the inhibitor, whichever is longer.\n* Unable to stop long-acting antihistamines within minimum wash out period required for SPTs at screening and site visits\n* History of or significant risk factor(s) for cardiovascular disease",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "50 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Yair Bitton, MBA, MPH",
                    "role": "CONTACT",
                    "phone": "347-466-2547",
                    "email": "yair.bitton@mssm.edu"
                },
                {
                    "name": "Scott Sicherer, MD",
                    "role": "CONTACT",
                    "email": "scott.sicherer@mssm.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Scott Sicherer, MD",
                    "affiliation": "Icahn School of Medicine at Mount Sinai",
                    "role": "STUDY_CHAIR"
                },
                {
                    "name": "Emma Guttman, MD, PhD",
                    "affiliation": "Icahn School of Medicine at Mount Sinai",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Icahn School of Medicine at Mount Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yair Bitton, MBA, MPH",
                            "role": "CONTACT",
                            "email": "yair.bitton@mssm.edu"
                        },
                        {
                            "name": "Scott Sicherer",
                            "role": "CONTACT",
                            "email": "scott.sicherer@mssm.edu"
                        },
                        {
                            "name": "Scott Sicherer, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "data will be provided as a manuscript"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006967",
                    "term": "Hypersensitivity"
                },
                {
                    "id": "D000005512",
                    "term": "Food Hypersensitivity"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000006969",
                    "term": "Hypersensitivity, Immediate"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "asFound": "Allergy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8636",
                    "name": "Food Hypersensitivity",
                    "asFound": "Food Allergy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10020",
                    "name": "Hypersensitivity, Immediate",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000634427",
                    "term": "Abrocitinib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M19117",
                    "name": "Immunoglobulins, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M1474",
                    "name": "Janus Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M274125",
                    "name": "Abrocitinib",
                    "asFound": "Left ventricle",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10121",
                    "name": "Immunoglobulin E",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}